Advertisement
The most recent proposals do allow for an increase in premiums that can beawarded. For innovative drugs, the premium range will be increased.
"To qualify for this premium in Japan, a product must have clinicallyuseful new mechanisms of action, must be proven to have greater efficacy orimproved safety and must demonstrate resultant, improved management of thetarget indication," said Stuart Bowman, director at Decision Resources."However, this premium is rarely awarded given the stringent, and less thantransparent, qualifying criteria."
Advertisement
The 2008 changes also herald the next round of biannual price cuts. Therewill likely be extraordinary price cuts for big-selling products, specificallyproducts for which sales have significantly exceeded original (official) salesprojections. Likely targets will be angiotensin II antagonists and SSRIs.
About Macroview from Decision Resources
Macroview is the most up-to-date analysis on events impacting thehealthcare industry. The Macroview updates are part of Decision Resources'Pharmaview product line, which offers a thorough analysis of thebiopharmaceutical sector from a therapy, industry and company point-of-view.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader inmarket research publications, advisory services and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources, Inc.
